Buyang Huanwu Decoction stabilizes atherosclerotic vulnerable plaques by regulating intestinal flora, TLR4-NF-κB-NLRP3 inflammatory pathway and mitophagy
Phytomedicine · 2025-07 · 142 · 156751
DOI: 10.1016/j.phymed.2025.156751 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2025-07. Verfasst von Shi-Yao Chang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Jiangxi University of Chinese Medicine, No. 1688 Meiling Avenue, Xinjian District, Nanchang, 330004 China. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Gastrointestinal Microbiome, Plaque, Atherosclerotic, Mitophagy. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Innovative Research Group Project of the National Natural Science Foundation of China, Jiangxi Provincial Natural Science Foundation.
Abstract (Originalsprache)
OBJECTIVE: This study explores the anti-atherosclerosis (AS) effects of Buyang Huanwu Decoction (BYHWD), focusing on its regulatory effects on the TLR4/NF-κB/NLRP3 inflammatory pathway, gut microbiota metabolites, and mitochondrial autophagy. Through the triple regulatory mechanisms of gut microbiota, the TLR4/NF-κB/NLRP3 inflammatory pathway, and mitochondrial autophagy, this study explores a novel strategy for stabilizing vulnerable AS plaques. MATERIALS AND METHODS: The active components of Buyang Huanwu Decoction (BYHWD) were detected using LC-MS/MS. By feeding a high-fat diet (HFD) and adding 1.3 % choline chloride to the drinking water to induce ApoE-/- mice gut microbiota dysbiosis, an AS mouse model with vulnerable plaques was established. The treatment groups were administered low, medium, and high doses of BYHWD, as well as broad-spectrum antibiotics. The effects of BYHWD on the vulnerable plaque area in the aorta, collagen content, macrophage and α-SMA protein expression, levels of inflammatory cytokines, reactive oxygen species (ROS), LC3 and NLRP3 expression, gut microbiota composition and abundance, serum trimethylamine-N-oxide (TMAO) levels, and the total bile acid content in the liver, serum, and gallbladder, as well as mitochondrial autophagy, were evaluated applying hematoxylin-eosin (HE) staining, Oil Red O staining, Sirius Red staining, immunohistochemistry, ELISA, immunofluorescence, 16S rRNA sequencing, biochemical analysis, and LC-MS detection. Western blot for TLR4, MyD88, ASC, pro-caspase-1, caspase-1, NLRP3, p-NF-κB/NF-κB, GPR41, GPR43, CYP7A1, CYP27A1, FMO3, FXR, TGR5, NIX, BNIP3, FUNDC1, PINK1, and Parkin proteins expression level. RESULTS: A total of 31 major active components were identified in Buyang Huanwu Decoction (BYHWD). BYHWD significantly reduced the vulnerable plaque area in the ApoE-/- mouse model of AS, decreased the expression of inflammatory cytokines, inhibited the protein expression of TLR4, MyD88, p-NF-κB/NF-κB, ASC, pro-caspase-1, NLRP3, FMO3, NIX, BNIP3, FUNDC1, and PINK1/Parkin in aortic tissues, downregulated ROS levels and mitochondrial autophagy activity, regulated gut microbiota abundance, reduced serum TMAO levels, and up-regulated the expression of gut microbiota-related proteins, including GPR41, GPR43, CYP7A1, CYP27A1, FXR, and TGR5. CONCLUSION: BYHWD exerts anti-AS effects through the inhibition of the TLR4/NF-κB/NLRP3 inflammatory pathway, modulating the gut microbiota, and stabilizing mitochondrial autophagy. The in-depth investigation of this mechanism effectively expands the therapeutic potential of BYHWD in the prevention and treatment of cardiovascular diseases and provides new theoretical insights and therapeutic targets for AS-related research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Jiangxi University of Chinese Medicine, No. 1688 Meiling Avenue, Xinjian District, Nanchang, 330004 China.
- Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, 330006 China. Electronic address: ndyfy02155@ncu.edu.cn.
- Department of Pharmacy, Jiangxi University of Chinese Medicine, No. 1688 Meiling Avenue, Xinjian District, Nanchang, 330004 China. Electronic address: 20070962@jxutcm.edu.cn.
Förderung
- National Natural Science Foundation of China
- Innovative Research Group Project of the National Natural Science Foundation of China
- Jiangxi Provincial Natural Science Foundation
Zitieren
APA
Chang, S. Y., Li, Y. T., Zhu, H. Y., He, Z. X., You, Y., & Liu, Y. H. (2025). Buyang Huanwu Decoction stabilizes atherosclerotic vulnerable plaques by regulating intestinal flora, TLR4-NF-κB-NLRP3 inflammatory pathway and mitophagy. Phytomedicine, 142, 156751. https://doi.org/10.1016/j.phymed.2025.156751
Vancouver
Chang SY, Li YT, Zhu HY, He ZX, You Y, Liu YH. Buyang Huanwu Decoction stabilizes atherosclerotic vulnerable plaques by regulating intestinal flora, TLR4-NF-κB-NLRP3 inflammatory pathway and mitophagy. Phytomedicine. 2025;142:156751. doi:10.1016/j.phymed.2025.156751
BibTeX
@article{Chang2025,
author = {Chang, Shi-Yao and Li, Yu-Ting and Zhu, Hong-Yang and He, Zhi-Xian and You, Yu and Liu, Yu-Hui},
title = {Buyang Huanwu Decoction stabilizes atherosclerotic vulnerable plaques by regulating intestinal flora, TLR4-NF-κB-NLRP3 inflammatory pathway and mitophagy},
journal = {Phytomedicine},
year = {2025},
volume = {142},
pages = {156751},
doi = {10.1016/j.phymed.2025.156751}
}
EUVIMED